Clinical Research Directory

Inclusion Criteria: Group 1: Dengue without warning signs Patients presenting with the following symptoms confirmed positive for dengue infection by lab diagnosis by anti-dengue IgM or NS1 ELISA will be recruited for the study under this cohort. Symptoms will be fever along with at least two of the following - * Myalgia, arthralgia * Nausea and/or vomiting * Rashes * Leukopenia Group 2: DENV with warning signs This cohort will include patients with the above symptoms and any of the following clinical signs. * Abdominal pain with tenderness * Persistent vomiting * Fluid accumulation * Mucosal bleeding * Restlessness, lethargy * Liver enlargement \>2cm * Laboratory findings: An increase in hematocrit levels and a rapid decrease in platelet count Group 3: Severe dengue * Severe plasma leakage leads to hypovolemic shock (dengue shock syndrome) and fluid accumulation with respiratory distress. * Severe bleeding, such as epistaxis, internal bleeding, etc., is evaluated by a clinician. * Severe organ involvement with any of the following symptoms * Liver AST or ALT ≥ 1000 * CNS: impaired consciousness * Heart and other organs failure Exclusion Criteria: \-